Results - Standalone Audited Financial results for the quater and financial year ended on 31st March 2026.
Awaiting price reaction for this filing.
Sarda Proteins Ltd reported revenue from operations of Rs. 1,525.85 Lakhs for FY26, down from Rs. 1,615.84 Lakhs in FY25. Net profit improved significantly to Rs. 63.79 Lakhs from just Rs. 0.50 Lakhs the prior year, with EPS rising to Rs. 3.70 from Rs. 0.03. However, the balance sheet shows significant changes: total assets surged to Rs. 8,661.06 Lakhs from Rs. 264.81 Lakhs, driven by large advances of Rs. 7,463.14 Lakhs and trade receivables of Rs. 426.54 Lakhs. The auditors received an unmodified opinion. A major red flag is the deeply negative operating cash flow of Rs. 7,638.85 Lakhs, mainly due to a Rs. 7,648.66 Lakhs increase in trade and other receivables. The company received Rs. 8,337.50 Lakhs as advance against equity shares pending allotment, which propped up financing cash flow.
While profit turned positive, the company faces serious cash flow concerns with negative operating cash flows and ballooning receivables. The large equity advance receipt is a non-recurring inflow that masks underlying operational weakness. Shareholders should monitor whether the pending equity allotment proceeds and how the company addresses the working capital strain.